Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completed

Nortriptyline and the Risk of Serious Adverse Events

NCT07527481
completedphase_3

Nortriptyline for Idiopathic Gastroparesis

NCT00765895
completedphase_1

Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma

NCT02881125

Clinical Trials (3)

Showing 3 of 3 trials
NCT07527481

Nortriptyline and the Risk of Serious Adverse Events

Completed
NCT00765895Phase 3

Nortriptyline for Idiopathic Gastroparesis

Completed
NCT02881125Phase 1

Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3